Barry M. Berger

4.1k total citations · 1 hit paper
55 papers, 2.8k citations indexed

About

Barry M. Berger is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barry M. Berger has authored 55 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 30 papers in Pathology and Forensic Medicine and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barry M. Berger's work include Colorectal Cancer Screening and Detection (32 papers), Genetic factors in colorectal cancer (27 papers) and Gastric Cancer Management and Outcomes (19 papers). Barry M. Berger is often cited by papers focused on Colorectal Cancer Screening and Detection (32 papers), Genetic factors in colorectal cancer (27 papers) and Gastric Cancer Management and Outcomes (19 papers). Barry M. Berger collaborates with scholars based in United States, Canada and Netherlands. Barry M. Berger's co-authors include David A. Ahlquist, Graham P. Lidgard, Thomas F. Imperiale, Steven H. Itzkowitz, Philip T. Lavin, Theodore R. Levin, David F. Ransohoff, Michael J. Domanico, William R. Taylor and Douglas W. Mahoney and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Barry M. Berger

52 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multitarget Stool DNA Testing for Colorectal-Cancer Screening

2014 1.3k citations Thomas F. Imperiale, Steven H. Itzkowitz et al. profile →

Peers

Barry M. Berger

ONCOL

PFM

PRM

Xavier Bessa Spain

Susan D. Richman United Kingdom

David Tougeron France

Claudio Bellevicine Italy

Aparna R. Parikh United States

Claus Fenger Denmark

Elena Vigliar Italy

Michael H. Veeder United States

Mara Ghilardi Italy

Jean-Marie Ledeine Belgium

Xavier Bessa Spain

Barry M. Berger

1.7k ×0.8

ONCOL

1.2k ×0.8

PFM

615 ×0.5

PRM

395 ×0.7

432 ×0.7

Citations per year, relative to Barry M. Berger Barry M. Berger (= 1×) peers Xavier Bessa

Countries citing papers authored by Barry M. Berger

Since Specialization

Citations

This map shows the geographic impact of Barry M. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry M. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry M. Berger more than expected).

Fields of papers citing papers by Barry M. Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry M. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry M. Berger. The network helps show where Barry M. Berger may publish in the future.

Co-authorship network of co-authors of Barry M. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Barry M. Berger. A scholar is included among the top collaborators of Barry M. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry M. Berger. Barry M. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roof, Scott A., Glenn J. Hanna, Eleni M. Rettig, et al.. (2024). The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.. Journal of Clinical Oncology. 42(16_suppl). e15045–e15045. 1 indexed citations

Kumar, Sunil, Cassin Kimmel Williams, Barry M. Berger, et al.. (2023). Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. Diagnostics. 13(4). 725–725. 27 indexed citations

Imperiale, Thomas F., Philip T. Lavin, Steven H. Itzkowitz, et al.. (2022). Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study. Cancer Prevention Research. 16(2). 89–97. 4 indexed citations

Frydman, Galit H., Barry M. Berger, Vadim Kostousov, et al.. (2022). Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation. Critical Care Explorations. 4(10). e0776–e0776.

Imperiale, Thomas F., et al.. (2021). Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study. Cancer Prevention Research. 14(4). 489–496. 39 indexed citations

Levin, Theodore R., Douglas A. Corley, Christopher D. Jensen, et al.. (2017). Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Digestive Diseases and Sciences. 62(3). 678–688. 11 indexed citations

Berger, Barry M., et al.. (2016). USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.. PubMed. 22(2). e77–81. 13 indexed citations

Berger, Barry M., Bernard Levin, & Robert J. Hilsden. (2016). Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines. World Journal of Gastrointestinal Oncology. 8(5). 450–450. 22 indexed citations

Heigh, Russell I., Tracy C. Yab, William R. Taylor, et al.. (2014). Detection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT). PLoS ONE. 9(1). e85659–e85659. 59 indexed citations

10.

Lidgard, Graham P., Michael J. Domanico, Janelle J. Bruinsma, et al.. (2013). Clinical Performance of an Automated Stool DNA Assay for Detection of Colorectal Neoplasia. Clinical Gastroenterology and Hepatology. 11(10). 1313–1318. 102 indexed citations

11.

Ahlquist, David A., Hongzhi Zou, Michael J. Domanico, et al.. (2011). Next-Generation Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas. Gastroenterology. 142(2). 248–256. 233 indexed citations

12.

Ahlquist, David A., William R. Taylor, Douglas W. Mahoney, et al.. (2011). The Stool DNA Test Is More Accurate Than the Plasma Septin 9 Test in Detecting Colorectal Neoplasia. Clinical Gastroenterology and Hepatology. 10(3). 272–277.e1. 128 indexed citations

13.

Li, Dan, Chengshi Jin, Charles E. McCulloch, et al.. (2009). Association of Large Serrated Polyps With Synchronous Advanced Colorectal Neoplasia. The American Journal of Gastroenterology. 104(3). 695–702. 117 indexed citations

14.

Itzkowitz, Steven H., Randall E. Brand, Lina Jandorf, et al.. (2008). A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection. The American Journal of Gastroenterology. 103(11). 2862–2870. 118 indexed citations

15.

Berger, Barry M., et al.. (2006). Colorectal Cancer Screening Using Stool DNA Analysis in Clinical Practice: Early Clinical Experience with Respect to Patient Acceptance and Colonoscopic Follow-up of Abnormal Tests. Clinical Colorectal Cancer. 5(5). 338–343. 24 indexed citations

16.

Berger, Barry M., et al.. (2003). Colon Cancer???Associated DNA Mutations: Marker Selection for the Detection of Proximal Colon Cancer. Diagnostic Molecular Pathology. 12(4). 187–192. 13 indexed citations

17.

Hutchinson, Martha L., et al.. (2000). Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.. PubMed. 6(7). 766–80. 24 indexed citations

18.

Berger, Barry M.. (1997). Using the Pathfinder System to Reduce Missed Abnormal Cervical Cytologic Smear Cases in a Rescreening Program. Acta Cytologica. 41(1). 173–181. 5 indexed citations

19.

Berger, Barry M.. (1996). Statistical Quality Assurance in Cytology. Acta Cytologica. 40(1). 97–106. 6 indexed citations

20.

Wilbur, David C., et al.. (1994). ThinPrep^™Processor:Clinical Trials Demonstrate an Increased Detection Rate of Abnormal Cervical Cytologic Specimens. American Journal of Clinical Pathology. 101(2). 209–214. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact